This video will address HIV pre-exposure prophylaxis, also known as HIV PrEP, as a means to prevent HIV-1 infection. It will cover a short description of what HIV is and some key players that assist in infecting the body. Moreover, it will focus on Truvada, the only approved HIV PrEP treatment in Canada and the United States.

This video was made by McMaster Demystifying Medicine students Kavena Sivakumar, Alice Nassar, Halla Rahman, Waleed Dhillon & Elise MacLean

Copyright McMaster University 2017

Please let us know how you liked this video and suggest additional topics for us to demystify below.

1. HIV, C. (2012). Aids. Medical Care, 916, 874-7720.

2. Palios, J., Kadoglou, N. P., & Lampropoulos, S. (2011). The pathophysiology ofHIV-/HAART-related metabolic syndrome leading to cardiovascular disorders

3. De Clercq, E. (2012). The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections
(AIDS). Advances in pharmacology (San Diego, Calif.), 67, 317-358) .

4. Ware, N. C., Wyatt, M. A., Haberer, J. E., Baeten, J. M., Kintu, A., Psaros, C., ... & Bangsberg, D. R. (2012). What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV serodiscordant couples. Journal of acquired immune deficiency syndromes (1999), 59(5)

5. PrEP | HIV Basics | HIV/AIDS | CDC. (2017). Cdc.gov. Retrieved 27 January 2017, Available at https://www.cdc.gov/hiv/basics/prep.html

6. Pizzuti, M. (2017). Who should or shouldn’t be on PrEP? A physician explains. pivotpdx.org. Retrieved 27 January 2017, Available at
http://pivotpdx.org/who-should-or-sho...

7. Gilead Sciences. (2016). Truvada: Highlights of Prescribing Information. Retrieved from: http://www.gilead.com/~/media/Files/p...

8. Peterson, L., Taylor, D., Roddy, R., Belai, G., Phillips, P., Nanda, K., ... & Jaffe, H. S. (2007). Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLOS Clin Trial, 2(5), e27.

9. Sharma, M., & Tan, D. H. (2014). HIV pre-exposure prophylaxis. Canadian Medical Association Journal, 186(15), E588-E588.

10. Grant, R. M., Anderson, P. L., McMahan, V., Liu, A., Amico, K. R., Mehrotra, M., ... & Buchbinder, S. (2014). Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. The
Lancet infectious diseases, 14(9), 820-829.

11. Spinner, C. D., Boesecke, C., Zink, A., Jessen, H., Stellbrink, H. J., Rockstroh, J. K., & Esser, S. (2016). HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of
oral systemic HIV PrEP in humans. Infection, 44(2), 151-158.

12. Hosek, S., Siberry, G., Bell, M., Lally, M., Kapogiannis, B., Green, K., ... & Wilson, C. (2013). Project PrEPare (ATN082): The acceptability and feasibility of an HIV pre-exposure prophylaxis (PrEP) trial with young men who have sex with men (YMSM).
Journal of acquired immune deficiency syndromes (1999), 62(4).